These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2095926)

  • 61. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
    Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
    J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.
    Decensi A; Robertson C; Viale G; Pigatto F; Johansson H; Kisanga ER; Veronesi P; Torrisi R; Cazzaniga M; Mora S; Sandri MT; Pelosi G; Luini A; Goldhirsch A; Lien EA; Veronesi U
    J Natl Cancer Inst; 2003 Jun; 95(11):779-90. PubMed ID: 12783932
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women.
    Grey AB; Stapleton JP; Evans MC; Reid IR
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3191-5. PubMed ID: 7593425
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Changes in serum hydroxyvitamin D levels of breast cancer patients during tamoxifen treatment or chemotherapy in premenopausal breast cancer patients.
    Kim HJ; Koh BS; Yu JH; Lee JW; Son BH; Kim SB; Ahn SH
    Eur J Cancer; 2014 May; 50(8):1403-11. PubMed ID: 24703104
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
    Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
    J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme.
    Powles TJ; Tillyer CR; Jones AL; Ashley SE; Treleaven J; Davey JB; McKinna JA
    Eur J Cancer; 1990; 26(6):680-4. PubMed ID: 2144154
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
    Göbel A; Kuhlmann JD; Link T; Wimberger P; Browne AJ; Rauner M; Hofbauer LC; Rachner TD
    Breast Cancer Res Treat; 2017 Aug; 164(3):737-743. PubMed ID: 28526959
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
    Abdel-Qadir H; Amir E; Fischer HD; Fu L; Austin PC; Harvey PJ; Rochon PA; Lee DS; Anderson GM
    Eur J Cancer; 2016 Nov; 68():11-21. PubMed ID: 27693889
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Tamoxifen--the treatment of choice. Why look for alternatives?
    Baum M
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):1-4. PubMed ID: 9741780
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tamoxifen in postmenopausal women a safety perspective.
    Robinson E; Kimmick GG; Muss HB
    Drugs Aging; 1996 May; 8(5):329-37. PubMed ID: 8935395
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent.
    Jordan VC; Fritz NF; Langan-Fahey S; Thompson M; Tormey DC
    J Natl Cancer Inst; 1991 Oct; 83(20):1488-91. PubMed ID: 1920495
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
    CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer.
    Li CI; Malone KE; Weiss NS; Daling JR
    J Natl Cancer Inst; 2001 Jul; 93(13):1008-13. PubMed ID: 11438566
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Early effects of adjuvant tamoxifen therapy on serum hormones, proteins and lipids.
    Kailajärvi M; Ahokoski O; Virtanen A; Salminen E; Irjala K
    Anticancer Res; 2000; 20(2B):1323-7. PubMed ID: 10810443
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.
    Cuzick J; Warwick J; Pinney E; Duffy SW; Cawthorn S; Howell A; Forbes JF; Warren RM
    J Natl Cancer Inst; 2011 May; 103(9):744-52. PubMed ID: 21483019
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long term effects of tamoxifen on blood lipid values in breast cancer.
    Dewar JA; Horobin JM; Preece PE; Tavendale R; Tunstall-Pedoe H; Wood RA
    BMJ; 1992 Jul; 305(6847):225-6. PubMed ID: 1392827
    [No Abstract]   [Full Text] [Related]  

  • 77. Long term effects of tamoxifen. Biological effects of Tamoxifen Working Party.
    Cuzick J; Allen D; Baum M; Barrett J; Clark G; Kakkar V; Melissari E; Moniz C; Moore J; Parsons V
    Eur J Cancer; 1992; 29A(1):15-21. PubMed ID: 1445735
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Breast cancer risk in relation to serum cholesterol, serum beta-lipoprotein, height, weight, and blood pressure.
    Törnberg SA; Holm LE; Carstensen JM
    Acta Oncol; 1988; 27(1):31-7. PubMed ID: 3365352
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tamoxifen as an antioxidant and cardioprotectant.
    Wiseman H
    Biochem Soc Symp; 1995; 61():209-19. PubMed ID: 8660396
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Selective changes in cholesterol metabolite levels in plasma of breast cancer patients after tumor removal.
    Soucek P; Vrana D; Ueng YF; Wei S; Kozevnikovova R; Guengerich FP
    Clin Chem Lab Med; 2018 Feb; 56(3):e78-e81. PubMed ID: 28915107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.